Adjunctive Lisdexamfetamine in Bipolar Depression

Trial Profile

Adjunctive Lisdexamfetamine in Bipolar Depression

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2014

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders; Depression
  • Focus Therapeutic Use
  • Acronyms Adjunctive-LDX-in-BP
  • Most Recent Events

    • 04 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top